Failures Declare Early: What the AUA 2026 BPH Failure Plenary Taught Me About Follow-Up
- Catherine Song, PhD.
- 6 days ago
- 4 min read
A field note from the AUA 2026 plenary on when BPH procedures fail.
I sat in on one of the more candid sessions at AUA 2026: a panel of experienced urologists walking through why BPH procedures fail, one technology at a time. As many of you know, I am not a urologist. I am here representing proudP, and I was in the audience taking notes. So this is a high-level account of what I captured, not a clinical interpretation, and I have surely missed nuance. For the underlying data and the full guideline context, go to the source.
What struck me was not the differences between the technologies. It was how much the panelists agreed on the pattern underneath all of them. Across UroLift, Rezum, HoLEP, TURP, and Aquablation, the same three ideas kept surfacing. Taken together, they point to one practical conclusion about follow-up.
Failures tend to declare themselves early
The most repeated phrase of the session was some version of "failures declare early." Most retreatments happen within the first year. One panelist put a finer point on it: if a patient is not clearly improving by three to six months, something is probably wrong, and that is the moment to stop reassuring and start investigating.
That reframes the early follow-up visit. The window where you can catch a failing result is not far out at a year. It is in those first months, when a clear signal of improvement either shows up or does not.
Most failures are explainable, not mysterious
The second theme: when a procedure does not deliver, the reason is usually findable. Several panelists made the point that the cystoscope often tells you why. A persistent median lobe. A device placed where it should not be. Residual tissue that was never treated. Failure was described again and again as anatomically explainable rather than random.
The takeaway is that good outcomes are built before the procedure, not rescued after it. Patient selection and pre-procedural assessment of prostate volume and shape came up in every talk. The recurring failure story was a technology used outside the anatomy it was designed for: a device meant for a moderate gland placed in a very large one, or a procedure that struggles with median lobes used on a prominent median lobe.
A technically successful procedure can still be a treatment failure
The third theme was the most human one, and the one I keep thinking about. A procedure can relieve the obstruction completely and the patient can still feel no better.
One case made this vivid. A man had his obstruction fully resolved, with a normal flow study afterward, yet remained miserable with nighttime urination. The real cause turned out to have nothing to do with his prostate. It was how much urine his body was making at night, tied in part to one of his other medications. The fix was a medication change, not more surgery. As the panelist put it, treating male urinary symptoms is more than relieving outlet obstruction, and surgical success is not the same as treatment success if the patient's quality of life and bother do not improve.
What this means for follow-up
Put the three together and the takeaway is straightforward. The early follow-up window matters more than it might seem, because that is when failures announce themselves. Catching them depends on having a clear, objective read of whether the patient is actually improving, not just a conversation about how he feels on a given day.
That was the spirit of the panel's closing discussion too. At the first post-procedure visit, the consensus was to stay measured: assess symptoms, rule out infection, check that the patient is emptying, and reserve invasive workup for the cases that warrant it. The first-line therapy, one panelist joked, is patience. But patience works best when it is informed by something you can actually track over those first few months.
That is the part that sits close to what we do. proudP gives clinicians and patients an objective, at-home read on urine flow over time, bladder diary and symptom scores, which is exactly the kind of early, repeatable signal this session kept circling back to. When the question is whether a patient is genuinely improving in the first three to six months, having a measurement to look at, rather than a memory, is the difference between catching a failure early and reassuring through it.
I would welcome corrections from those of you who know this material far better than I do. The cases and data belong to the panelists; the through-line is just what I heard, sitting in the room.
Frequently asked questions
When do most BPH procedure failures show up? Panelists at the AUA 2026 failure plenary noted that most retreatments occur within the first year, and that poor symptom improvement by three to six months is a strong early signal that something is wrong.
Why do BPH procedures fail? The recurring reasons discussed were patient selection (using a technology outside the prostate anatomy it suits), technique, and persistent or untreated tissue. Panelists emphasized that failures are usually anatomically explainable rather than random.
Can a BPH procedure be technically successful but still fail the patient? Yes. Panelists stressed that relieving the obstruction does not always relieve the symptoms. Storage dysfunction, nocturnal polyuria, medications, and comorbidities can all leave a patient bothered after a technically successful procedure.